Bruce Czarnik, MD
Cardiovascular Disease · Saint Louis, MONPI 1114974532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Abbott at 28.7% of the total.
Across 102 payments — averaging $33.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$978
- Kestra Medical Technology Services, Inc.$346
- E.r. Squibb & Sons, L.L.C.$327
- Cvrx, Inc.$195
- Boston Scientific$194
- Abiomed$148
- plus $1K from 17 others
Across 41 payments — averaging $1869.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$77K
What the payments were for
- Food & beverage$3,411100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 37 | $978 |
| Kestra Medical Technology Services, Inc. | 10 | $346 |
| E.r. Squibb & Sons, L.L.C. | 12 | $327 |
| Cvrx, Inc. | 2 | $195 |
| Boston Scientific | 3 | $194 |
| Abiomed | 1 | $148 |
| Actelion Pharmaceuticals US, Inc. | 2 | $148 |
| AstraZeneca | 2 | $145 |
| Itamar Medical Inc | 1 | $120 |
| Edwards Lifesciences | 1 | $115 |
| Sanofi-aventis U.S. LLC | 1 | $115 |
| Lantheus Medical Imaging, Inc. | 4 | $86 |
| Pfizer | 4 | $74 |
| Medtronic | 3 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $71 |
| Johnson & Johnson | 3 | $55 |
| Amgen | 3 | $44 |
| Heartflow, Inc. | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Novartis | 2 | $37 |
| Astellas Pharma US Inc | 1 | $23 |
| Philips North America LLC | 1 | $18 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$179
- Assure WCD$159
- Impella$148
- UPTRAVI$134
- OPSUMIT$134
- WATCHMAN FLX$125
- FARXIGA$123
- CAMZYOS$122
- WatchPATONE$120
- SAPIEN 3 Ultra RESILIA$115
- PRALUENT$115
- Confirm Rx$106
How this compares
$3,411 in reported general payments places this provider in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 900 | $1,036,584 |
| VyndamaxTafamidis | 28 | $764,859 |
| XareltoRivaroxaban | 185 | $232,625 |
| Repatha SureclickEvolocumab | 249 | $212,062 |
| EntrestoSacubitril/Valsartan | 137 | $184,159 |
| JardianceEmpagliflozin | 93 | $113,455 |
| FarxigaDapagliflozin Propanediol | 93 | $107,096 |
| Praluent PenAlirocumab | 43 | $31,838 |
| MultaqDronedarone Hcl | 19 | $20,619 |
| BrilintaTicagrelor | 14 | $12,984 |
| Metoprolol Succinate | 802 | $9,735 |
| Repatha SyringeEvolocumab | 17 | $7,844 |
| Atorvastatin Calcium | 646 | $4,816 |
| Rosuvastatin Calcium | 440 | $4,182 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 113 | $3,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $74 | $1,801,443928 claims |
| Johnson & JohnsonXarelto | $55 | $232,625185 claims |
| NovartisEntresto | $37 | $184,159137 claims |
| AstraZenecaFarxiga, Brilinta | $145 | $120,080107 claims |
| Sanofi-aventis U.S. LLCMultaq | $115 | $20,61919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.